Miromatrix Medical Inc. (NASDAQ:MIRO) Q3 2022 Results Conference Call November 14, 2022 4:30 PM ET

Company Participants

Hannah Jeffrey - IR

Jeff Ross - CEO

Jim Douglas - CFO

Operator

Greetings, and welcome to the Miromatrix Medical Inc.'s Third Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.

It is now my pleasure to introduce your host, Hannah Jeffrey. Thank you. Please go ahead.

Hannah Jeffrey

Good afternoon, and thank you for joining us.

Earlier today, Miromatrix released financial results for the quarter and nine months ended September 30, 2022. The release is currently available on the Company's website at www.miromatrix.com.

Jeff Ross, Chief Executive Officer; and Jim Douglas, Chief Financial Officer, will host this afternoon's call.

Before we get started, I would like to remind everyone that management will be making statements during this call that include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Any statements contained in this call that are not statements of historical fact, including statements regarding the potential timing of pre-IND filings and IND clearances, the initiation of related clinical trials, future expenses and revenue, capital requirements, cash runway and needs for additional financing should be deemed to be forward-looking statements.

All forward-looking statements are based upon current estimates and various assumptions. These statements involve material risks and uncertainties that could cause actual results to differ materially from those anticipated or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these statements. For a list and description of materials and risks, uncertainties associated with our business, please see our filings with the Securities and Exchange Commission.

The information provided in this conference call speaks only to the live broadcast today, November 14, 2022. Miromatrix disclaims any intention or obligation, except as required by law, to update or revise any information, financial projections or other forward-looking statements, whether because of new information, future events or otherwise.

I will now turn the call over to Jeff.

Jeff Ross

Thanks, Hannah. Good afternoon, and thank you, everyone, who has joined us today for our third quarter 2022 earnings call.

I am proud to announce what many have been waiting to hear. We recently filed our IND application for miroliverELAP with the FDA. We are pioneering a new class of medicine and believe that this is the first IND to be submitted to the FDA for a bioengineered organ, putting us one step closer to realizing our goal of saving and improving patients' lives and eliminating the organ transplant waiting list. We will wait for the FDA's feedback and plan to initiate a Phase 1 clinical trial shortly after receiving their clearance. I'm incredibly proud of our entire team for achieving this important milestone.